title: Biomarkers in cancer immunotherapy.
abstract: Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer-immunity cycle.
authors.affiliation: Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands. Electronic address: t.schumacher@nki.nl.
authors.forename: Ton N
authors.initials: TN
authors.lastname: Schumacher
authors.affiliation: Department of Theoretical Biology and Bioinformatics, Utrecht University, 3584 CH Utrecht, the Netherlands.
authors.forename: Can
authors.initials: C
authors.lastname: Kesmir
authors.affiliation: Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
authors.forename: Marit M
authors.initials: MM
authors.lastname: van Buuren
mesh_terms: D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000235:genetics / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000912:Antibodies, Neoplasm; D014408:Biomarkers, Tumor